Business Wire

Xsolla Enables U.S. Google Play Game Developers to Add External Purchase Links Inside Their Games

29.10.2025 21:00:00 EET | Business Wire | Press release

Share

Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced that it can now power external purchases for Android developers following Google’s policy updates in the United States.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029226256/en/

(Graphic: Xsolla)

Beginning October 29, 2025, U.S. developers can legally include external purchase links in their Google Play games, ending longstanding exclusivity and paving the way for more flexible, direct-to-consumer monetization strategies.

With this industry-defining change, Xsolla’s Buy Button and Web Shop solutions provide immediate, compliant pathways for developers to diversify their mobile commerce, maintain player relationships, and optimize revenue. For more than a decade, Android game developers have been forced to rely on Google Play’s in-app billing system for transactions. Today’s policy shift marks a turning point as developers can now direct players to secure, web-based checkout flows under their own brand and business logic. Xsolla’s Buy Button and Web Shop solutions are built to help developers seamlessly leverage this new flexibility and launch sales outside app store ecosystems.

Xsolla’s Web Shop is a full-service, branded e-commerce storefront for selling virtual items, currency, and bundles outside the app store ecosystem. Developers retain ownership of customer data and can leverage marketing tools, loyalty programs, and promotions to build stronger player connections. Together, these solutions allow developers to expand beyond platform constraints while maintaining compliance and player experience integrity.

“Google’s update opens the door for developers to finally take control of their mobile commerce,” said Chris Hewish, President of Xsolla. “With our Buy Button and Web Shop solutions, studios can move fast, connect directly with their players, and keep more of their hard-earned revenue. This is a pivotal step toward a more open and equitable mobile gaming ecosystem.”

The ability to add external purchase links in Android games represents one of the most significant shifts in the mobile industry since app stores were introduced. Following Apple’s earlier move to open iOS in select regions, this evolution on Android underscores the growing global momentum toward more open mobile ecosystems. For developers, these changes unlock opportunities to build direct-to-consumer relationships, reduce dependency on third-party billing systems, optimize revenue with flexible pricing and global payment options, and deliver better player experiences through custom offers and loyalty rewards. Similar updates are anticipated across the UK, Europe, Japan, and Brazil, signaling a broader industry transition toward greater flexibility and fairness in mobile game monetization.

Xsolla’s established global infrastructure spanning payments, tax and compliance, fraud prevention, and player fulfillment positions developers to quickly and securely adopt external purchase strategies.

​​Developers ready to take advantage of Google’s new policy can get started today with Xsolla Buy Button and Xsolla Web Shop, proven, secure solutions built for fast integration and global scalability. Learn how to launch your own direct-to-consumer monetization strategy and take full control of your mobile business at: xsolla.blog/android-dev

About Xsolla

Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.

For more information, visit xsolla.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251029226256/en/

Contacts

Media Contact
Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye